secwatch / observer
8-K filed November 1, 2022, 7:59 PM ET ticker TECH CIK 0000842023
earnings confidence high sentiment positive materiality 0.75

Bio-Techne Q1 FY2023 revenue up 7% organic, GAAP EPS $2.21, declares 4-for-1 stock split

BIO-TECHNE Corp

2023-Q1 EPS reported $2.21 revenue$269,655,000

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BIO-TECHNE Corp: Increased authorized shares of common stock from 100,000,000 to 400,000,000 (effective 2022-10-27).

Change
charter amendment
Effective
2022-10-27
Exact text from the filing
At the 2022 annual meeting of shareholders of the Company held on October 27, 2022 (the “Annual Meeting”), the shareholders approved an amendment and restatement of the Company’s articles of incorporation to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 400,000,000.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

BIO-TECHNE Corp shareholders approved The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement at the 2022-10-27 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2022-10-27
Exact text from the filing
Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: For Against Abstain Broker Non-Vote 21,321,031 13,045,755 286,774 1,070,883
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

BIO-TECHNE Corp shareholders approved The shareholders ratified an amendment to increase the number of shares of authorized common stock at the 2022-10-27 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2022-10-27
Exact text from the filing
Proposal No. 4 – The shareholders ratified an amendment to increase the number of shares of authorized common stock. For Against Abstain ​ 35,648,572 68,310 7,561
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

BIO-TECHNE Corp shareholders approved The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023 at the 2022-10-27 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2022-10-27
Exact text from the filing
Proposal No. 5 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023. For Against Abstain ​ 34,862,262 856,480 5,701
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

BIO-TECHNE Corp shareholders approved The shareholders elected each of the nominees to the Board of Directors at the 2022-10-27 meeting.

Proposal
director election
Outcome
passed
Meeting
2022-10-27
Exact text from the filing
Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: ​ For Against Abstain Broker Non-Vote Charles R. Kummeth 34,092,428 546,544 14,588 1,070,883 Robert V. Baumgartner 24,822,872 9,195,158 635,530 1,070,883 Randolph C. Steer 31,246,852 3,392,776 13,932 1,070,883 John L. Higgins 27,963,915 6,675,747 13,898 1,070,883 Roeland Nusse 33,805,594 834,332 13,634 1,070,883 Julie L. Bushman 34,398,791 242,354 12,415 1,070,883 Joseph D. Keegan 32,918,324 1,721,906 13,330 1,070,883 Alpna Seth 33,163,651 1,475,674 14,235 1,070,883 Rupert Vessey 32,917,182 1,721,925 14,453 1,070,883 Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

BIO-TECHNE Corp shareholders approved The shareholders voted to set the number of directors at nine at the 2022-10-27 meeting.

Outcome
passed
Meeting
2022-10-27
Exact text from the filing
Proposal No. 1 – The shareholders voted to set the number of directors at nine: ​ For Against Abstain ​ 35,575,971 139,956 8,516
View on SEC.gov

Browse all governance changes →

BIO-TECHNE Corp filing history →

Source: SEC EDGAR
accession 0001558370-22-015710
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.